Latham & Watkins represented Sobi in the transaction. Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus (nirsevimab) in the United...
Sanofi, AstraZeneca and Sobi’s Streamlining of Nirsevimab Contractual Arrangements
Indivior’s $145 Million Acquisition of Opiant Pharmaceuticals
Covington & Burling LLP advised Indivior, while Latham & Watkins LLP represented Opiant in the transaction. Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) has entered into a definitive...
LG Chem’s Acquisition of AVEO Oncology
Latham & Watkins LLP represented LG Chem in the transaction, while WilmerHale LLP represented AVEO. LG Chem, Ltd. (KOSPI: 051910) entered into a definitive agreement to acquire...
Cytokinetics’ $540 Million Convertible Senior Notes Offering
Latham & Watkins represented the initial purchasers in the offering while Cooley advised Cytokinetics. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, has announced the pricing of its...
Ligand’s Spin-off of OmniAb Business
Latham & Watkins represented Ligand in the transaction, while Weil, Gotshal & Manges represented APAC. Ligand Pharmaceuticals Incorporated has announced the signing of a definitive merger...
Waldencast’s $1.2 Billion Business Combination With Obagi and Milk Makeup
Skadden, Arps, Slate, Meagher & Flom represented Waldencast. Latham & Watkins, working alongside Conyers and Nixon Peabody, represented Obagi, and Goodwin Procter represented Milk Makeup in...
GlaxoSmithKline’s Collaboration with Alector
Latham & Watkins LLP represented GSK in the transaction. Alector, Inc. and GlaxoSmithKline plc, announced a strategic global collaboration for the development and commercialization of two...
GlaxoSmithKline’s Collaboration with Alector
Latham & Watkins LLP represented GSK in the transaction. Alector, Inc. and GlaxoSmithKline plc, announced a strategic global collaboration for the development and commercialization of two...